Atossa Genetics (ATOS)
(Delayed Data from NSDQ)
$0.85 USD
-0.03 (-3.55%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $0.84 -0.01 (-1.03%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth C Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ATOS 0.85 -0.03(-3.55%)
Will ATOS be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ATOS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ATOS
Are Medical Stocks Lagging Atossa Genetics (ATOS) This Year?
All You Need to Know About Atossa Genetics (ATOS) Rating Upgrade to Buy
ATOS: What are Zacks experts saying now?
Zacks Private Portfolio Services
TCMD Stock Rises 20% in Three Months: Should You Buy, Hold or Sell?
Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year?
Is Intuitive Surgical (ISRG) Outperforming Other Medical Stocks This Year?
Other News for ATOS
Is ATOS showing upside potential? 200 Day Moving Average Support shows up after sinking 3.55%
ATOS Crossed Above 200 Day Moving Average on September 18
Atossa Therapeutics: Strategic Advancements and Strong Financial Position Signal Promising Future
ATOS forms 50 Day Moving Average Support on September 17
Atossa Therapeutics appoints CORE IR for investor relations